Guardant Health Inc
NASDAQ:GH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.07
38.11
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Guardant Health Inc
Guardant Health Inc. emerged from the convergence of innovation and necessity, pioneering a transformative approach to cancer diagnostics. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on the potential of liquid biopsy technology. Unlike traditional biopsies that often require invasive procedures, Guardant Health's tests analyze circulating tumor DNA (ctDNA) from a simple blood draw. This standout technology not only provides critical insights into the genomic profile of tumors but also facilitates early cancer detection, treatment monitoring, and recurrence detection, breaking new grounds in precision oncology. The company's flagship product, Guardant360, plays a pivotal role for oncologists by enabling tailored treatment plans based on real-time, dynamic insights into the cancer's genetic mutations.
Earning its revenue primarily through partnerships with healthcare providers, pharmaceutical companies, and research institutions, Guardant Health has positioned itself strategically in the medical diagnostics landscape. By offering tests that can be repeatedly adapted to monitor the evolution of cancer over time, the company garners significant interest as it aids in the development of targeted cancer therapies. Pharmaceutical companies, in particular, collaborate with Guardant Health to utilize its technology in clinical trials to identify suitable candidates and assess treatment efficacy. The company's growing influence is further bolstered by its commitment to expanding applications for early cancer detection, laying the groundwork for potential shifts in cancer care paradigms. Thus, Guardant Health, through its innovative fusions of technology and healthcare, forges ahead in transforming cancer management and diagnostics, turning its story into a testament of modern medical advancement.
Guardant Health Inc. emerged from the convergence of innovation and necessity, pioneering a transformative approach to cancer diagnostics. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on the potential of liquid biopsy technology. Unlike traditional biopsies that often require invasive procedures, Guardant Health's tests analyze circulating tumor DNA (ctDNA) from a simple blood draw. This standout technology not only provides critical insights into the genomic profile of tumors but also facilitates early cancer detection, treatment monitoring, and recurrence detection, breaking new grounds in precision oncology. The company's flagship product, Guardant360, plays a pivotal role for oncologists by enabling tailored treatment plans based on real-time, dynamic insights into the cancer's genetic mutations.
Earning its revenue primarily through partnerships with healthcare providers, pharmaceutical companies, and research institutions, Guardant Health has positioned itself strategically in the medical diagnostics landscape. By offering tests that can be repeatedly adapted to monitor the evolution of cancer over time, the company garners significant interest as it aids in the development of targeted cancer therapies. Pharmaceutical companies, in particular, collaborate with Guardant Health to utilize its technology in clinical trials to identify suitable candidates and assess treatment efficacy. The company's growing influence is further bolstered by its commitment to expanding applications for early cancer detection, laying the groundwork for potential shifts in cancer care paradigms. Thus, Guardant Health, through its innovative fusions of technology and healthcare, forges ahead in transforming cancer management and diagnostics, turning its story into a testament of modern medical advancement.